Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of authorized generic version of Par Pharmaceutical’s VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market was approved by the U.S. Food and Drug Administration (USFDA).
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
September 02, 2022
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio
Details : Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines and Vasostrict is a RFLD.
Product Name : Vasostrict-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Launches 4 New Generic Products, Including Vasopressin Single-dose
Details : Vasopressin injection 1mL is a generic version of the antidiuretic hormone Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Arm Gets Final US FDA Nod for Vasopressin injection
Details : Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shocks, such as due to post-cardiotomy or sepsis, and remain hypotensive despite fluids and catecholamines.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
August 16, 2022
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
Details : In August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
December 29, 2021
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Par Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
December 29, 2021
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Par Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
Details : This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
December 15, 2021
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation
Details : United States District Court for the District of Delaware's non-infringement found non-infringement of Endo's patents by Eagle's proposed ANDA for Par Sterile Products, LLC's VASOSTRICT® product, it did not rule on the patents' validity.
Product Name : Vasostrict
Product Type : Peptide
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
Details : Eagle is first to file an Abbreviated New Drug Application (“ANDA”) referencing Vasostrict®, which had total U.S. sales of $786 million in 2020.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S. FDA has issued a complete response letter for Eagle's Abbreviated New Drug Application for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA within 30 days.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable